摘要：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整
编者按：第47届圣安东尼奥乳腺癌研讨会（SABCS）将于当地时间2024年12月10日至13日在美国得克萨斯州圣安东尼奥举行。SABCS是全球最大的乳腺癌领域盛会，来自102个国家的超过1万名注册参会者将在为期四天的会议中展示1886篇被接受的论文摘要。肿瘤瞭望特别整理中国专家被收录的壁报内容，以飨读者。（注：因官网未公布详细作者单位，如有遗漏或错误，欢迎留言指正。）
Poster Session 3
日期：12月12日
时间：12:30～2:00 p.m.
地点：Halls 2-3
P3-01-19: Proteomics-based degradome analysis of mammary tumor adjacent adipocyte reveals adipocyte-derived peptide MASP6 promotes breast cancer cell invasion and migration
基于蛋白质组学的乳腺肿瘤邻近脂肪细胞降解组分析揭示脂肪细胞来源的肽MASP6促进乳腺癌细胞的侵袭和迁移
报告作者：Shuhan Zhao
P3-02-05: Mitochondrial Metabolism-Related Features Guiding Precision Subtyping and Prognosis in Breast Cancer, Revealing FADS2 as a Novel Therapeutic Target
线粒体代谢相关特征指导乳腺癌的精确分型和预后，并揭示FADS2为新型治疗靶点
报告作者：Yangyang Cui
P3-02-17: tRF-1432–a novel target for reversing chemoresistance in breast cancer
tRF-1432——逆转乳腺癌化疗耐药性的新靶点
报告作者：Yuhan Dai
P3-02-22: The role of circular RNAs in triple-negative breast cancer and chemotherapy resistance
环状RNA在三阴性乳腺癌及化疗耐药性中的作用
报告作者：Xiyin Wang
P3-02-26: Sex-biased cancer cells induce endocrine therapy resistance and immune suppression in male breast cancer
性别偏向性癌细胞在男性乳腺癌中诱导内分泌治疗耐药和免疫抑制
报告作者：Zhishuang Gao
P3-02-27: circAXIN1 promotes EMT-mediated metastasis and doxorubicin resistance via Wnt/β-catenin pathway by regulating miR-486-3p/BCL11A axis in TNBC
circAXIN1通过Wnt/β-catenin途径调节miR-486-3p/BCL11A轴，促进三阴性乳腺癌（TNBC）中EMT介导的转移和阿霉素耐药
报告作者：YAN LIU
P3-02-28: A combination approach to target residual tumors via ferroptosis induction
通过诱导铁死亡靶向残留肿瘤的组合方法
报告作者：Yulin Li
P3-02-29: The mechanism of acidic microenvironment promotes tumor-associated macrophages secreting glutamine to activate dual signaling pathways of mTORC1 and c-MYC in CDK4/6 inhibitor resistance of ER-positive breast cancer
酸性微环境机制促进肿瘤相关巨噬细胞分泌谷氨酰胺激活ER阳性乳腺癌CDK4/6抑制剂耐药的mTORC1和c-MYC双信号通路
报告作者：Fanli Qu
P3-03-15: Racial differences in incidence of depression, anxiety, and insomnia among breast cancer patients on endocrine therapy
内分泌治疗期间乳腺癌患者抑郁、焦虑和失眠发病率的种族差异
报告作者：Shuwen Lin
P3-03-17: Genetic Profiles and Precision Medicine in Adolescent and Young Adult Chinese Women with Breast Cancer: A Comprehensive Study
中国青少年和年轻女性乳腺癌的遗传学特征和精准医学：一项综合研究
报告作者：Qing Hao
P3-04-06: Genomic and transcriptomic profiling of BRCA mutation carrier tissues reveals the landscape of early pathogenesis of BRCA1/2-associated breast cancer
BRCA突变携带者组织的基因组和转录组特征揭示了BRCA1/2相关乳腺癌的早期发病机制全貌
报告作者：Zuen Ren
P3-04-22: An organoid model derived from a patient with breast angiosarcoma
源自乳腺血管肉瘤患者的类器官模型
报告作者：Xiaoling Liu
P3-04-27: Resistance to neratinib in HER2+ breast cancer: Mechanistic insights and treatment approaches
HER2+乳腺癌对奈拉替尼的耐药性：机制见解与治疗方法
报告作者：Fu-Tien Liao
P3-05-22: Prognostic Significance of Tumor-informed Personalised Circulating Tumor DNA Monitoring in Breast Cancer Patients Undergoing Neoadjuvant Therapy
基于肿瘤的个体化循环肿瘤DNA监测对新辅助治疗乳腺癌患者的预后意义
报告作者：Yunjiang Liu
P3-06-15: Trajectories of Daily Step Counts in Breast Cancer Survivors in the Breast Cancer Weight Loss (BWEL) Trial
乳腺癌减肥试验（BWEL）中乳腺癌幸存者每日步数轨迹的研究
报告作者：Chao Cao
P3-06-16: Heterogeneity of Tertiary Lymphoid Structures Predicts the Response to Neoadjuvant Therapy and Immune Microenvironment Characteristics in Triple-Negative Breast Cancer
三级淋巴样结构的异质性可预测三阴性乳腺癌对新辅助治疗的反应及免疫微环境特征
报告作者：Chuangui Song
P3-06-17: IAPP mediated anti-breast cancer function of CD8+T cells via targeting cuproptosis
IAPP通过靶向铜死亡介导CD8+T细胞的抗乳腺癌功能
报告作者：Zhijian Huang
P3-06-30: Novel Humanized LIV-1 Antibody Based ADCs Conjugated with Topoisomerase I Inhibitor Payloads Displayed Significantly Higher Anti-tumor Activities than MMAE based ADCs in TNBC Tumor Models
在TNBC肿瘤模型中，新型人源化的基于拓扑异构酶I抑制剂的ADC比基于MMAE的adc具有更高的抗肿瘤活性
报告作者：Xueming Qian
P3-07-01: Comparative effectiveness and safety of initial operation in inoperable locally advanced breast cancer—a realworld retrospective cohort study in China
中国不可手术局部晚期乳腺癌初始手术疗效与安全性的比较——一项真实世界回顾性队列研究
报告作者：Yan Lin
P3-07-04: Postoperative upper Limb Edema & Dysfunction Generated by axillary nodes Excision w/ or w/out axillary vein branches reservation in breast cancer patients (PLEDGE-Surgery):a prospective,multiple-center,double-blinded, randomized controlled study
乳腺癌患者腋窝淋巴结切除术中保留或不保留腋窝静脉分支对术后上肢水肿及功能障碍的影响（PLEDGE-Surgery）：一项前瞻性、多中心、双盲、随机对照研究
报告作者：Qianrui Xu
P3-07-21: Transcriptomic analysis of the tumor immune microenvironment (TIME) in patients with breast cancer with liver metastasis (BCLM)
乳腺癌肝转移（BCLM）患者肿瘤免疫微环境（TIME）的转录组学分析
报告作者：Jiayi Tan
P3-07-24: Real-World Treatment Patterns and Clinical Outcomes of Sacituzumab Govitecan in HER2 negative metastatic breast cancer patients in China
中国HER2阴性转移性乳腺癌患者中戈沙妥珠单抗的真实世界治疗模式及临床结局
报告作者：Huanhuan Zhou
P3-07-30: Mesenchymal Stem Cells Regulate E-cadherin Level, Proliferation, and Immuno-Resistance on Breast Cancer Cells
间充质干细胞对乳腺癌细胞E-钙粘蛋白水平、增殖和免疫抗性的调控作用
报告作者：Bei Dai
P3-08-14: Analysis of the Occurrence Time of Bone Metastasis and Disease Treatment Patterns in 737 Patients with Breast Cancer Bone Metastasis: A Retrospective Study from China
中国737例乳腺癌骨转移患者骨转移发生时间及疾病治疗模式分析：一项回顾性研究
报告作者：Xiaojia Wang
P3-08-30: Development of humanized anti-FABP4 monoclonal antibodies for potential treatment of breast cancer
人源化抗FABP4单克隆抗体的开发用于乳腺癌的潜在治疗
报告作者：Bing Li
P3-09-11: Effect of Removed Lymph Nodes Number on Survival in Node-negative Early Breast Cancer: A Multicenter Retrospective Study (CSOBO YOUNG-03)
淋巴结切除数量对淋巴结阴性早期乳腺癌患者生存期的影响：一项多中心回顾性研究（CSOBO YOUNG-03）
报告作者：Ke-Da YU
P3-10-13: A Comprehensive Analysis of Dysregulation in the PTEN/PI3K/AKT Pathway in Breast Cancer Among the Chinese Population
中国乳腺癌患者中PTEN/PI3K/AKT通路失调的综合分析
报告作者：Ziang Li
P3-10-23: RecurIndex Predicts Risk of Recurrence in Early-stage Luminal Breast Cancer: APRIL Trial
RecurIndex预测早期管腔型乳腺癌复发风险：APRIL试验
报告作者：Lei Lei
P3-11-12: (Neo)adjuvant Therapy Patterns and Outcomes in Patients with HR-Positive/HER2-Positive Early or Locally Advanced Breast Cancer: a Real-World Study Using National Cancer Information Database, China
HR阳性/HER2阳性早期或局部晚期乳腺癌患者的（新）辅助治疗模式及结局：基于中国国家癌症信息数据库的真实世界研究
报告作者：Zhenzhen Liu
P3-11-14: Differential response to neoadjuvant antiHER2 therapy between HER2 2+ISH+ and HER2 3+ in HER2-positive breast cancer: Is HER2 2+ISH+ a distinct subtype?
HER2阳性乳腺癌中HER2 2+ISH+与HER2 3+对新辅助抗HER2治疗的反应差异：HER2 2+ISH+是否为一种独特亚型？
报告作者：Lingjun Ma
P3-11-16: Personalized Neoadjuvant Therapy Guided by Drug Screening of Patient-Derived Tumor-Like Cell Clusters in HER2- Positive Breast Cancer: A Prospective Phase II Study and Exploratory Analysis
基于患者来源肿瘤样细胞簇药物筛选指导的HER2阳性乳腺癌个性化新辅助治疗：一项前瞻性II期研究及探索性分析
报告作者：Yaqian Xu
P3-11-19: Efficacy of different neoadjuvant systemic treatment regimens in Chinese patients with HER2-positive advanced breast cancer: a real-world retrospective multi-center cohort study
中国HER2阳性晚期乳腺癌患者不同新辅助全身治疗方案的疗效：一项真实世界回顾性多中心队列研究
报告作者：Xiaoming Zha
P3-11-24: Neoadjuvant Nab-paclitaxel combined with Trastuzumab and Pyrotinib for HER2-enriched subtype of HER2- positive early or locally advanced breast cancer: A multicenter,single-arm, phase 2 trial
白蛋白结合型紫杉醇联合曲妥珠单抗和吡咯替尼用于HER2富集型HER2阳性早期或局部晚期乳腺癌的新辅助治疗：一项多中心、单臂、II期临床试验
报告作者：Wenbin Zhou
P3-11-26: A Phase II study of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer
达尔西利联合来曲唑、帕妥珠单抗和曲妥珠单抗作为HR+/HER2+乳腺癌新辅助治疗的II期研究
报告作者：曾晓华（重庆大学附属肿瘤医院）
P3-12-03: Optimizing Treatment Sequence for Inoperable LABC:Long-Term Outcomes of Surgery First vs. NeoadjuvantChemotherapy in a Real-World Setting
优化不可手术局部晚期乳腺癌（LABC）的治疗顺序：真实世界中先行手术vs新辅助化疗的长期结果比较
报告作者：Yu Song
P3-12-09: Evaluation of the Early Risk of Recurrence in HR+/HER2- Early Breast Cancer Patients – A Retrospective Study Based on the Chinese National Cancer Database
基于中国国家癌症数据库的HR+/HER2-早期乳腺癌患者早期复发风险评估——一项回顾性研究
报告作者：Qiao Li
P3-12-22: Neoadjuvant Therapy with Pyrotinib, Subcutaneous Trastuzumab, and Capecitabine for HER2-Positive Early Breast Cancer: A Prospective, Single-Arm, Multicenter Trial
吡咯替尼联合皮下注射曲妥珠单抗和卡培他滨用于HER2阳性早期乳腺癌的新辅助治疗：一项前瞻性、单臂、多中心试验
来源：肿瘤瞭望
